Risedronate for the prevention of fractures in postmenopausal osteoporosis

Annals of Pharmacotherapy

Volumn 36, Issue 4, 2002, Pages 664-670

  Sickels, Jennifer M ^a   Nip, Chi Sing ^a   Rivera Miranda, Giselle C ^a   Rudis, Maria ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Fractures; Postmenopausal osteoporosis; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN;

ABDOMINAL PAIN; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HORMONE SUBSTITUTION; HUMAN; MEDLINE; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; VERTEBRA FRACTURE;

EID: 0036208751     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A221     Document Type: Article

References (19)

1. NIH Consensus Development Panel on osteoporosis prevention, diagnosis, and therapy
2. Osteoporosis: Epidemiology, diagnosis, and treatment
3. Treatment of postmenopausal osteoporosis
4. Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis: Status report
5. The worldwide problem of osteoporosis: Insights afforded by epidemiology
6. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials
7. The pharmacology and therapeutic utility of bisphosphonates
8. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausai osteoporosis
9. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
10. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
11. A 2-year Phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal women
12. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
13. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial
14. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
15. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
16. Effect of risedronate on the risk of hip fracture in elderly women